Ernexa Therapeutics Inc. (ERNAW)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 2.5M 5M 7.5M Q3 '18: 6M Q4 '18: 5.9M Q1 '19: 4.8M Q2 '19: 5.2M Q3 '19: 4.6M Q4 '19: 5.2M Q1 '20: 2.4M Q2 '20: 754K Q3 '20: 1.5M Q4 '20: 1.2M Q3 '22: 0 Q4 '22: 0 Q1 '23: 0 Q2 '23: 0 Q3 '23: 51K Q4 '23: 17K Q1 '24: 47K Q2 '24: 47K Q3 '24: 487K Q4 '24: 1K Q4 '18 Q3 '19 Q2 '20 Q3 '22 Q2 '23 Q1 '24 Q4 '24

Gross Profit Quarterly

-200K 0 200K 400K 600K Q3 '22: 0 Q4 '22: 0 Q1 '23: -50K Q2 '23: 0 Q3 '23: -69K Q4 '23: -49K Q1 '24: -14K Q2 '24: -48K Q3 '24: 547K Q4 '24: 1K Q4 '22 Q2 '23 Q4 '23 Q2 '24 Q4 '24

Operating Income Quarterly

-90M -60M -30M 0 30M 60M 90M Q3 '21: -86.3M Q4 '21: -8.5M Q1 '22: -6.3M Q2 '22: -13.9M Q3 '22: -8.3M Q4 '22: -4.7M Q1 '23: -5.3M Q2 '23: -4.5M Q3 '23: -5.5M Q4 '23: -5.8M Q1 '24: -5.8M Q2 '24: -4.9M Q3 '24: -2.3M Q4 '24: -2.7M Q1 '25: -2.7M Q2 '25: -2.5M Q3 '25: -2M Q4 '25: -2.1M Q1 '26: -5.6M Q2 '26: -4.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-90M -60M -30M 0 30M 60M 90M Q3 '21: -86M Q4 '21: -8M Q1 '22: -9.4M Q2 '22: -3.4M Q3 '22: -7.3M Q4 '22: -4.5M Q1 '23: -5.4M Q2 '23: -4.5M Q3 '23: -5.6M Q4 '23: -6.2M Q1 '24: -6.6M Q2 '24: -5.5M Q3 '24: -26.6M Q4 '24: -5.8M Q1 '25: -8.2M Q2 '25: -3.1M Q3 '25: -1.2M Q4 '25: -1.5M Q1 '26: -5.5M Q2 '26: -4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

-100K -50K 0 50K 100K 150K Q3 '22: 0 Q4 '22: 0 Q1 '23: 50K Q2 '23: 0 Q3 '23: 120K Q4 '23: 66K Q1 '24: 61K Q2 '24: 95K Q3 '24: -60K Q4 '24: 0 Q2 '25: 0 Q2 '26: 0 Q4 '22 Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '26

Operating Cash Flow Quarterly

-7.5M -5M -2.5M 0 2.5M 5M 7.5M Q3 '21: -6.4M Q4 '21: -6.8M Q1 '22: -5.4M Q2 '22: -4M Q3 '22: -6.1M Q4 '22: -5.4M Q1 '23: -6M Q2 '23: -3.9M Q3 '23: -5.8M Q4 '23: -4.7M Q1 '24: -3.7M Q2 '24: -2.3M Q3 '24: -6.3M Q4 '24: -3.5M Q1 '25: -2.1M Q2 '25: -2.5M Q3 '25: -1.3M Q4 '25: -1.1M Q1 '26: -2.3M Q2 '26: -4.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-7.5M -5M -2.5M 0 2.5M 5M 7.5M Q4 '20: -1.7M Q1 '21: -3.4M Q2 '21: -6.8M Q3 '21: -6.4M Q4 '21: -7M Q1 '22: -5.5M Q2 '22: -4.2M Q3 '22: -6.2M Q4 '22: -5.5M Q1 '23: -6M Q2 '23: -3.9M Q3 '23: -5.8M Q4 '23: -4.7M Q1 '24: -3.8M Q2 '24: -2.5M Q3 '24: -6.3M Q4 '24: -3.5M Q4 '25: -1.2M Q1 '26: -2.3M Q2 '26: -4.2M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15M 30M 45M Q1 '20: 17.5M Q2 '20: 17.6M Q3 '20: 17.6M Q1 '21: 27.8K Q2 '21: 42.4M Q3 '21: 2.5M Q1 '22: 2.7M Q2 '22: 2.9M Q3 '22: 2.9M Q1 '23: 5.1M Q2 '23: 5.3M Q3 '23: 5.4M Q1 '24: 5.4M Q2 '24: 361K Q3 '24: 361K Q1 '25: 142K Q2 '25: 207K Q3 '25: 8.2M Q1 '26: 792K Q2 '26: 1.2M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-120.00 -80.00 -40.00 0.00 40.00 80.00 120.00 Q4 '19: -0.71 Q1 '20: -0.66 Q2 '20: -0.75 Q3 '20: -0.74 Q4 '20: -0.41 Q1 '22: -37.59 Q2 '22: -38.51 Q3 '22: -6.97 Q4 '22: -8.17 Q1 '23: -5.73 Q2 '23: -5.42 Q3 '23: -3.96 Q4 '23: -4.08 Q1 '24: -4.25 Q2 '24: -18.74 Q3 '24: -91.41 Q4 '24: -48.96 Q1 '25: -105.49 Q2 '25: -105.34 Q3 '25: -31.79 Q1 '20 Q4 '20 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.